SYBLEU

SYBLEU ROIC

The Return on Invested Capital (ROIC) of SYBLEU (SYBE) as of Nov 1, 2026 is -142.53 %. In the previous year, Return on Invested Capital (ROIC) was 223.09 % — a change of -163.89% (lower).

ROIC

-142.53 %

YoY

-163.89%

Last updated:

Return on Invested Capital (ROIC) of SYBLEU is 2023 -142.53 % . Return on Invested Capital (ROIC) of SYBLEU was 2022 223.09 % . It decreases by -163.89% lower compared to the previous year.

The SYBLEU ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2020
-45.88 USD
Jan 1, 2021
-2,369.77 USD
Jan 1, 2022
223.09 USD
Jan 1, 2023
-142.53 USD
The SYBLEU ROIC history
YEARROICYoY
-142.53 %-163.89%
223.09 %-109.41%
-2,369.77 %+5,064.88%
-45.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SYBLEU Stock analysis

What does SYBLEU do? SYBLEU Inc develops regenerative medical applications focused on therapies for human and animal health, medical devices, and clinical diagnostics. The company generates revenue through the sale or licensing of its developed applications after completing Phase I or Phase II clinical trials, or by advancing them to Phase III trials. It also develops disposable medical devices and explores artificial intelligence and machine learning applications in clinical diagnostics. SYBLEU Inc targets the healthcare sector with its innovative medical solutions. The firm's primary products include therapies for human and animal health, medical devices, and clinical diagnostics. It also develops drugs for treating cancer in companion animals, leveraging artificial intelligence and machine learning in its diagnostic processes. SYBLEU Inc's business model relies on advancing its applications through clinical trials to either secure licensing deals or commercialize its products directly. SYBLEU Inc's target market segments are healthcare providers, veterinary clinics, and medical device manufacturers seeking innovative regenerative therapies and diagnostic tools. The company's focus on companion animal cancer treatments and AI-enhanced diagnostics positions it within specialized segments of the medical industry. Its development of disposable medical devices further expands its reach into the broader healthcare market. SYBLEU is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SYBLEU stock

Return on Invested Capital (ROIC) of SYBLEU is -142.53 % in 2023.

Return on Invested Capital (ROIC) of SYBLEU changed from 223.09 % to -142.53 %, representing a -163.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) SYBLEU since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s SYBLEU with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SYBLEU

All Key Metrics — SYBLEU